Literature DB >> 22321137

Epidemic of Mycoplasma pneumoniae infection in Denmark, 2010 and 2011.

S A Uldum1, J M Bangsborg, B Gahrn-Hansen, R Ljung, M Mølvadgaard, R Føns Petersen, C Wiid Svarrer.   

Abstract

Denmark experienced two waves of Mycoplasma pneumoniae infection during autumn and early winter in 2010 and 2011, respectively. Both affected the whole country. The proportion of positive results was almost the same for both, indicating that the two waves were probably of equal size. High macrolide consumption during the epidemics did not seem to affect levels of macrolide resistance in M. pneumoniae, which remain low in Demark (1% to 3%).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22321137     DOI: 10.2807/ese.17.05.20073-en

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  26 in total

1.  Mycoplasma pneumoniae and health outcomes in children with asthma.

Authors:  Pamela R Wood; Jordan C Kampschmidt; Peter H Dube; Marianna P Cagle; Paola Chaparro; Norma S Ketchum; Thirumalai R Kannan; Harjinder Singh; Jay I Peters; Joel B Baseman; Edward G Brooks
Journal:  Ann Allergy Asthma Immunol       Date:  2017-06-19       Impact factor: 6.347

2.  First report of macrolide resistance in a Mycoplasma pneumoniae isolate causing community-acquired pneumonia in Spain.

Authors:  Juan de Dios Caballero; Rosa del Campo; María Del Carmen Mafé; María Gálvez; Mario Rodríguez-Domínguez; Rafael Cantón; María Antonia Meseguer; José Manuel Hermida
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

3.  Long-Term Low Rate of Macrolide-Resistant Mycoplasma pneumoniae Strains in Germany.

Authors:  Roger Dumke; Thomas Ziegler
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 4.  Mycoplasma pneumoniae from the Respiratory Tract and Beyond.

Authors:  Ken B Waites; Li Xiao; Yang Liu; Mitchell F Balish; T Prescott Atkinson
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

5.  Low rate of macrolide resistance in Mycoplasma pneumoniae strains in Germany between 2009 and 2012.

Authors:  Roger Dumke; Christian Lück; Enno Jacobs
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

6.  Genetic diversity and macrolide resistance of Mycoplasma pneumoniae isolates from two consecutive epidemics in Slovenia.

Authors:  R Kogoj; M Praprotnik; T Mrvič; M Korva; D Keše
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-09-26       Impact factor: 3.267

7.  Mycoplasma pneumoniae in children with acute and refractory asthma.

Authors:  Pamela R Wood; Vanessa L Hill; Margaret L Burks; Jay I Peters; Harjinder Singh; Thirumalai R Kannan; Shruthi Vale; Marianna P Cagle; Molly F R Principe; Joel B Baseman; Edward G Brooks
Journal:  Ann Allergy Asthma Immunol       Date:  2013-02-23       Impact factor: 6.347

8.  Investigations of Mycoplasma pneumoniae infections in the United States: trends in molecular typing and macrolide resistance from 2006 to 2013.

Authors:  Maureen H Diaz; Alvaro J Benitez; Jonas M Winchell
Journal:  J Clin Microbiol       Date:  2014-10-29       Impact factor: 5.948

9.  Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients.

Authors:  Yasuhiro Kawai; Naoyuki Miyashita; Mika Kubo; Hiroto Akaike; Atsushi Kato; Yoko Nishizawa; Aki Saito; Eisuke Kondo; Hideto Teranishi; Satoko Ogita; Takaaki Tanaka; Kozo Kawasaki; Takashi Nakano; Kihei Terada; Kazunobu Ouchi
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

10.  Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients.

Authors:  Yasuhiro Kawai; Naoyuki Miyashita; Mika Kubo; Hiroto Akaike; Atsushi Kato; Yoko Nishizawa; Aki Saito; Eisuke Kondo; Hideto Teranishi; Tokio Wakabayashi; Satoko Ogita; Takaaki Tanaka; Kozo Kawasaki; Takashi Nakano; Kihei Terada; Kazunobu Ouchi
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.